UNSPSC 51162418: Guaifenesin/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.

UNSPSC 51162418 Guaifenesin/pseudoephedrine is a Commodity code that captures state and local procurement of specific pharmaceutical products, though recent opportunities tagged under this code show significant scope mismatch. The two recent opportunities in the record—one for naloxone and drug deactivation systems (Seminole County, Florida) and one for generic multi-source pharmaceuticals and OTC products through a multistate cooperative (Minnesota Multistate Cooperative Purchasing Alliance)—do not align with the code's nominal focus on a single active pharmaceutical ingredient combination. The naloxone procurement is an emergency-response medical supply unrelated to guaifenesin/pseudoephedrine; the MMCAP RFP covers a broad portfolio of generic and OTC drugs across multiple therapeutic categories, not this specific combination. State and local agencies issuing under this code appear to include county health departments and state-administered cooperative purchasing entities serving multiple jurisdictions and member agencies.

The geographic activity shown is limited to Florida and Minnesota, with the MMCAP cooperative extending participation to Oregon and other unspecified participating jurisdictions. Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, under a two-year term with one-year renewal option. The Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishes contracts for generic pharmaceuticals and OTC products across multistate member facilities, with awarded vendors effective July 1, 2026. The code shows limited recent relevant activity—the mismatch between the code's specific pharmaceutical focus and the actual work being solicited suggests either misclassification by the issuing bodies or that this code segment sees infrequent state and local procurement activity.